QR-Code

The Third Dose of BNT162b2 COVID-19 Vaccine Does Not “Boost” Disease Flares and Adverse Events in Patients with Rheumatoid Arthritis

Data on the risk of adverse events (AEs) and disease flares in autoimmune rheumatic diseases (ARDs) after the third dose of COVID-19 vaccine are scarce. The aim of this multicenter, prospective study is to analyze the clinical and immunological safety of BNT162b2 vaccine in a cohort of rheumatoid ar...

Ausführliche Beschreibung

Gespeichert in:
Hauptverfasser: Andrea Picchianti Diamanti, Assunta Navarra, Gilda Cuzzi, Alessandra Aiello, Simonetta Salemi, Roberta Di Rosa, Chiara De Lorenzo, Daniele Vio, Giandomenico Sebastiani, Mario Ferraioli, Maurizio Benucci, Francesca Li Gobbi, Fabrizio Cantini, Vittoria Polidori, Maurizio Simmaco, Esmeralda Cialdi, Palma Scolieri, Vincenzo Bruzzese, Emanuele Nicastri, Raffaele D’Amelio, Bruno Laganà, Delia Goletti
Format: Artigo
Sprache:Inglês
Veröffentlicht: MDPI AG 2023-02-01
Schriftenreihe:Biomedicines
Schlagworte:
COVID-19
SARS-CoV-2 vaccine
immunogenicity
adverse events
disease flare
autoimmune rheumatic diseases
Online-Zugang:https://www.mdpi.com/2227-9059/11/3/687
Tags: Tag hinzufügen
Keine Tags, Fügen Sie das erste Tag hinzu!

Ähnliche Einträge